Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FLT3-ITD Positive AML~* Allo-HSCT Recipients~Exclusion Criteria:~* cardiac dysfunction (particularly congestive heart failure)~* hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase\> 2 times the upper limit of normal)~* renal dysfunction (creatinine clearance rate \< 30 mL/min)~* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)~* Patients with any conditions not suitable for the trial (investigators' decision)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Sorafenib group (Type: EXPERIMENTAL): Sorafenib will be used from day 30 to 180 post-transplantation.
- non-Sorafenib group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).